The purpose of this statement is to determine the optimal HPV immunization schedule in groups for whom HPV vaccine is recommended in Canada, and to summarize the evidence reviewed by other immunization technical advisory groups, including the World Health Organization’s (WHO’s) Strategic Advisory Group of Experts (SAGE) on immunization, on the effect of a 2-dose HPV vaccine schedule, compared with the 3-dose schedule authorized for use of both bivalent (Cervarix® [HPV2]) and quadrivalent (Gardasil® [HPV4]) HPV vaccines. As of May 2013, Cervarix® has been authorized for use in females 9-45 years of age (expanded from 10-26 years of age). On July 3, 2014, Cervarix® was authorized for use in Canada as a 2-dose schedule (0, 6 months) in girls 9 to 14 years of age at the time of first injection.
This statement will:
- Provide an overview of previous NACI recommendations for HPV immunization
- Outline the national goal for HPV immunization, and current status of HPV immunization programs in Canada
- Summarize the evidence reviewed and evidence-based recommendations made by other immunization technical advisory groups that informed the development of this statement
- Provide recommendations for the optimal HPV immunization schedule in Canada
- Recommendation
- Americas
- Canada
- Human papillomavirus (HPV)
